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Abstract: Intrinsically disordered proteins and regions (IDPs and IDRs) lack well-defined tertiary 
structures, yet carry out various important cellular functions, especially those associated with cell 
signaling and regulation. In eukaryotes, IDPs and IDRs contain the preferred loci for both 
alternative splicing (AS) and many post-translational modifications (PTMs). Furthermore, AS 
and/or PTMs at these loci generally alter the signaling outcomes associated with these IDPs or 
IDRs, where the functional cooperation of these three features is named the IDP-AS-PTM toolkit. 
However, the prevalence of such functional modulations remains unknown. Also, the signal-
altering mechanisms by which AS, and PTMs modulate function and the extent to which AS and 
PTMs collaborate in their signaling modulations have not been well defined for particular protein 
examples. Here we focus on three important signaling and regulatory IDR-containing protein 
families in humans, namely G-protein coupled receptors (GPCRs), which are transmembrane   
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proteins, the nuclear factors of activated T-cells (NFATs), which are transcription factors (TFs), 
and the Src family kinases (SFKs), which are signaling enzymes. The goal here is to determine 
how AS and PTMs individually alter the outcomes of the signaling carried out by the various IDRs 
and to determine whether AS and PTMs work together to bring about differential cellular 
responses. We also present data indicating that a wide range of other signaling IDPs or IDRs 
undergo both AS- and PTM-based modifications, suggesting that they, too, likely take advantage 
of signal outcome modulations that result from collaboration between these two events. Hence, 
we propose that the widespread cooperation of IDPs, AS and/or PTMs provides a IDP-AS-PTM 
toolkit and substantially contributes to the vast complexity of eukaryotic cell signaling systems. 
Keywords: Intrinsic disorder, alternative splicing, post-translational modification, differential and 
context-dependent signaling, signaling modulation, and regulation 
Abbreviations: IDPs or IDRs, intrinsically disordered proteins or regions; AS, alternative splicing; 
PTMs, post-translational modifications; GPCRs, G-protein coupled receptors; NFATs, nuclear 
factor of activated T-cells; TFs, transcription factors; SFKs, Src family kinases; CD, circular 
dichroism; NMR, nuclear magnetic resonance; ICL3, intercellular loop 3; CaN, calcineurin; GRK, 
G-protein coupled receptor kinase; PKA/C, protein kinase A/C; CDK, cyclin-dependent kinase;
DBD, DNA-binding domain. 
Highlights 
 We propose that IDPs work in concert with AS and PTMs to provide an IDP-AS-PTM toolkit
for complex context-dependent cell signaling and regulation. 
 Three intensely studied, highly divergent signaling protein families, namely G-protein
coupled receptors (GPCRs), nuclear factor of activated T-cells (NFAT) transcription factors (TFs) 
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and Src family kinases (SFKs), all use this toolkit to increase context-dependent signaling 
complexity. 
 PubMed text mining shows the widespread occurrence of IDPs, AS and PTMs in a large 
number of proteins including those involved in developmental signaling pathways, which indicates 
a common maybe even universal use of the IDP-AS-PTM toolkit in eukaryotic multicellular 
signaling systems. 
Introduction 
Intrinsically disordered proteins and regions (IDPs and IDRs) have been found to be heavily 
involved in cell signaling and regulation, especially in eukaryotes[1-9]. Due mainly to their amino 
acid compositions[10-12], IDPs and IDRs lack stable tertiary structures under physiological 
conditions and exist instead in highly dynamic, interconverting, flexible conformations[13]. Their 
functions complement those of structured proteins and underlie cellular differentiation, 
transcription, cell cycle regulation, DNA condensation, cell division and many other crucial 
biological processes[3, 14]. 
Protein/nucleic acid/ligand binding sites are often located in IDPs or IDRs, and their flexibility 
enable single, short IDRs to change their backbone and side-chain conformations and thereby 
bind tightly with multiple, distinctly shaped binding partner surfaces[15, 16]. Thus IDPs and IDRs 
can mediate interactions with a large number of partners and thus function as hubs or as partners 
to structured hub proteins in signaling networks[17-19]. Furthermore, IDPs and IDRs contain 
numerous sites for post-translational modifications (PTMs) that can reversibly regulate IDP- or 
IDR-binding in a cellular context-dependent manner by adding binding sites for new partners 
and/or by inhibiting binding by partners that recognize the unmodified IDR, thus further expanding 
an IDR’s already formidable binding repertoire. In many cases the PTM-induced changes lead to 
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initiation or inhibition of specific signaling pathways[20-23], or can be involved in diseases[24] or 
protein translocation[25]. Another way of expanding the functionality of IDPs and IDRs is through 
alternative splicing (AS) of pre-mRNA that codes for the same IDP or IDR, a post-transcriptional 
process that generates two or sometimes many more protein forms from a single gene[26]. These 
versatilities offered by the flexibility of IDPs or IDRs, with AS and PTMs adding further complexity, 
enable signaling and regulatory proteins to efficiently accomplish dynamic functions in response 
to changes in cellular environments. 
Based on the observation that both AS and PTMs, especially multiple PTMs[27, 28], alter the 
functions of many IDPs[23, 26], we previously proposed that IDPs work cooperatively with AS 
and PTMs to provide a toolkit (namely IDP-AS-PTM), for signaling diversification[29, 30]. We also 
showed that this toolkit is used by many of the proteins that carry out the functions underlying 
multicellularity, functions such as cell-to-cell adhesion, intercellular communication, development 
pathway specification, development pathway regulation over space and time, and tissue- or cell-
type-specific physiology[31]. An important feature of this proposal is that tissue- or cell-type-
specificity has been shown for both AS[32, 33] and PTMs[34, 35], suggesting that the new 
biological function enabled by the IDP-AS-PTM toolkit provides context-dependent signaling. By 
this we mean that specific tissues or specific cell-types are able to “rewire” or “remodel” protein 
pathways and genetic networks depending on the local context, while still using the same sets of 
genes. This rewiring results from the tissue- or cell-type-specific AS and/or the tissue- or cell-
type-specific PTMs. That is, both AS and PTMs have been shown to have the capability to alter 
interactions between proteins or between proteins and nucleic acids, and both undergo tissue- or 
cell-type specific alterations[16, 26, 32, 33, 36-38]. 
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So far, a significant number of important protein families have been predicted to contain 
substantial amounts of intrinsic disorder. Some families have been analyzed in a large scale 
(genome- or proteome-wide), including transcription factors[39, 40], nuclear hormone 
receptors[41], membrane proteins[42, 43], histones[44], spliceosomal proteins[45, 46], ribosomal 
proteins[47], DNA/RNA binding proteins[48], and many enzymes[49]. Other proteins have been 
investigated on a smaller scale, but with detailed features (e.g. domain organizations, molecular 
recognition features, binding interface properties), such as serine-arginine rich proteins[50], 
scaffold proteins[51], autoinhibited proteins[52], cytoskeletal proteins[53]. In addition, many IDPs 
are associated with human diseases, including cancer, neurondegeneration, cardiovascular 
disease, amyloidosis, diabetes and many others[2, 54]. While more IDPs continue to be 
characterized thus expanding the biological functions known to be associated with these 
proteins[49, 55, 56], the frequency of occurrence of the IDP-AS-PTM toolkit mentioned above 
remains unknown, and how IDPs or IDRs, AS and/or PTMs jointly regulate these proteins is not 
well characterized for any particular IDP or IDR. 
Here we examine whether the IDP-AS-PTM toolkit is used by three important signaling and 
regulatory IDP families in humans, all of which contain members involved in development, namely 
the G-protein coupled receptors (GPCRs, a membrane receptor protein family), the nuclear 
factors of activated T-cells (NFATs, a transcription factor (TF) family), and the proto-oncogene 
Src family kinases (SFKs, a regulatory enzyme family). First we map the sequence locations of 
sites associated with AS (annotated in UniProt) and PTM (annotated in UniProt and 
PhosphoSitePlus[57]), and then we determine whether their IDRs are enriched in these two 
regulatory events as compared to their structured regions. Next we study selected examples for 
each family to determine whether, and if so, how IDRs, AS and PTMs collaborate to regulate 
signaling diversity for these particular protein examples. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
6 
 
GPCRs are of particular interest because they are the largest known seven transmembrane 
(7TM) protein family that have a particularly high amount of predicted disorder as compared to 
other transmembrane proteins[43]. This a very large membrane receptor protein family with over 
800 members in humans, with an enormous diversity of ligands from rhodopsin to peptides, and 
with involvement in an extremely wide range of biological processes, including blood pressure 
regulation, olfactory function, embryogenesis and nearly every other physiological process[58, 
59]. 
TFs play a particularly central role in transcription regulation. Particular TF examples have 
been known to contain IDRs since the 1980s[60], nearly two decades before bioinformatics 
examinations showed the widespread existence of massive amounts of intrinsic disorder in the 
eukaryotic TFs[39, 40]. Among the many well studied IDR-containing TFs, the NFAT family was 
selected because it has widespread importance, including critical roles in T-cell function, 
inflammation, angiogenesis, myocardial development, skeletal muscle development, cancer 
metastasis, and many other biological processes; because its own regulation depends on two 
very important signaling systems, namely regulation by calcium levels with calmodulin as the 
calcium sensor and regulation by phosphorylation by various kinases and dephosphorylation by 
calcineurin [61], and because its massive IDRs have been characterized by both circular 
dichroism (CD) and nuclear magnetic resonance (NMR)[62]. 
SFKs are non-receptor tyrosine kinases, and they are key regulators in signal transduction. 
The first-discovered SFK member, Src, is identified as the most highly connected hub in the 
whole kinome. Members of this family are predicted to contain large IDRs at their N- or C-
terminus or between folded domains, and these predicted IDRs are significantly overlapped by 
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regions of missing electron density from available SFK structures[63]. Also, SFKs help to regulate 
a number of important processes such as differentiation, proliferation, migration, and survival[64]. 
For these three particular protein families, and many other IDPs mentioned above, numerous 
publications show that their functional complexity is substantially enhanced by the combined use 
of IDPs or IDRs, AS and/or PTMs. These observations support our hypothesis that the IDP-AS-
PTM toolkit is commonly used to provide a mechanism for sophisticated signaling processes and 
indeed may be essential for the emergence of complex multicellular organisms as we suggested 
previously[31]. 
Results 
GPCRs and the IDP-AS-PTM toolkit 
Co-occurrence of IDRs, AS and PTMs in GPCRs 
The full-length GPCRs include the extracellular N-terminus, the intracellular C-terminus, 
seven transmembrane helices (TM1-7), three intracellular loops (ICL1-3) and three extracellular 
loops (ECL1-3) connecting the helices. While the overall TM topology is well conserved across 
GPCR members, the N-terminus, ICL3 and the C-terminus exhibit high variability in terms of 
length and amino acid composition[65], and are predicted to be the most disordered regions 
(green histogram in Fig. 1A, left). This result is consistent with previous predictions[65-67] and the 
experimental confirmation on a few GPCRs by CD and NMR[68-70]. In addition, these results 
agree with the necessary truncation of these IDRs for most GPCRs during crystallization. Indeed, 
for the >200 available crystal structures belonging to 44 GPCRs in Protein Data Bank (PDB), a 
majority of their N- and C-termini and ICL3 regions are truncated to achieve crystallization 
success. 
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In accordance with the distribution of IDRs over GPCR secondary structures, the occurrence 
of both AS and PTMs (purple line in Fig. 1A and stacked bar in Fig. 1B, respectively) more often 
localize within the N- and C-termini and ICL3 regions as compared to other regions. Experimental 
data provides evidence that GPCRs can be modified in multiple ways, and undergo tissue-
specific AS (Fig.1C), suggesting those two regulatory phenomena may mutually alter specific 
receptor functions. Indeed, Among the 308 AS regions, 94 (~31%) of them contain known PTM 
sites that may be altered by AS (Fig.2A). More importantly, as shown in the disorder distribution 
in Fig. 2B, when predicted to be fully ordered (disorder percentage=0%), AS regions with PTMs 
show lower percentage of than those without known PTMs (18% and 41% respectively); in 
opposite, when predicted to be disordered, AS regions with PTMs generally show higher 
percentage than those of without PTMs (Fig. 2B). This result suggests that AS regions with PTMs 
are more likely to predicted to be disordered, indicating that IDRs provide the preferential 
locations for AS to modulate PTMs. This enrichment of AS and multiple PTMs within IDRs of 
GPCRs provide massive combinations of IDR, AS and/or PTMs that would differentially “encode” 
receptor functional diversity, including differential downstream cellular signaling. 
Regulation of GPCR functions by IDR-localized AS and/or PTMs 
Given the preference of IDRs, AS and PTMs within N-terminus, ICL3 and C-terminus of 
GPCRs, in the following we explore how these three most disordered regions work in concert with 
AS and/or PTMs to enhance receptor functional diversity in a cell- or tissue- specific manner.  
In general, the disordered regions of GPCRs are important for receptor ligand binding, 
surface expression, trafficking and signaling, thus alteration of them by AS would substantially 
affect GPCR activities. For instance, AS-isoforms differ in the N-terminus of many GPCRs show 
decreased or abolished ligand-binding activity[71, 72]. In many cases, the functions of N-
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terminus-associated AS-variants remain to be elucidated, and some are speculated to act as a 
dominant-negative mutant of the wild-type receptors[71]. Interestingly, some GPCRs have a very 
long disordered ICL3 regions, within which the AS events often occur. For instance D2 dopamine 
receptor (DRD2), with a long ICL3 having 148 residues, generates three isoforms, D2short, 
D2long (canonical) and D2longer, with D2short and D2longer having deletion of 29 residues and 
insertion of two residues in ICL3, respectively[73, 74]. As a result, D2short and D2long couple 
with different α subunit of inhibitory G-proteins (D2short coupled preferentially with Gαi1, and 
D2long couples selectively with Gαi2) and activate distinct signaling pathways accordingly[75]. 
The free fatty acid receptor 4 (FFAR4) generates an isoform with insertion of 16 residues within 
ICL3, leading the receptor towards an arrestin-biased pathway[76]. Another extreme case is 
CXCR3 isoform CXCR3Alt, which lacks the whole ICL3 region and fails to induce either Gαi 
activation or β-arrestin recruitment[77]. As ICL3 is important for G-protein or arrestin interaction 
and subsequent activation of intracellular events[78], other GPCRs with AS-isoforms differing 
within this disordered region [e.g. D3 dopamine receptor (34 residues deletion), 
Gastrin/cholecystokinin type B receptor (69 residues insertion), Histamine H3 receptor (80 
residues deletion)] are likely to have different signaling pathways or especially biased signaling 
pathways, thus illustrating the essential roles of IDR-localized AS in selective signal transduction. 
A large number of phosphorylation sites are localized within the IDRs of GPCRs (Fig.1B), 
and have been described to generate different combinational patterns linked to differential GPCR 
signaling. Such patterns, which are termed phosphorylation codes, were initially discovered in 
M3-muscarinic acetylcholine receptor[79] and β2AR[80], and are found in disordered C-tails/ICL3 
for most GPCRs[81]. Besides phosphorylation, other PTMs, such as palmitoylation[82], 
glycosylation[83], different patterns of ubiquitination (mono- or poly-ubiquitination)[84], also 
participate in biased signaling, suggesting the likely presence of an expanded version to the 
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phosphorylation code ––a PTM code that specifies GPCR activities using different types of PTMs. 
The potential to regulate distinct signaling outcome by combinatorial PTMs is illustrated by 
studies on CXCR4, which undergoes not only sulfation and glycosylation, but also 
phosphorylation and ubiquitination (Fig.3). Thus, in the case of CXCR4, there is evidence that 
site-specific PTMs can result in different signaling results, supporting the GPCR PTM code 
hypothesis mentioned in reference[85]. 
AS further modulates PTM incidence in GPCRs 
AS can alter multiple PTMs sites for many GPCRs (Fig1C and Fig.2), leading to another 
layer of functional complexity by combining IDR-Co-occurring with AS and PTMs. This agrees 
well with the functional influence of tissue-specific AS on IDPs in general[32, 33]. For example, 
among the six GPCRs that undergo palmitoylation (Fig.1C), four of them (AVPR2[86], EDNRB 
and EDNRA[87], OPRM1[88]) lose their palmitoylation sites induced by AS. AVPR2 isoform 
without the palmitoylation sites (C341 and C342) and phosphorylation sites (S362, S363 and 
S364) can adopt two different topologies[89] and mainly remain inside the cell and down-
regulates the surface expression of canonical AVPR2 by formation of heterodimers[90]. EDNRB 
isoforms that lack the palmitoylation sites fail to activate G proteins[91]. Replacement of 
phosphorylation sites within disordered C-terminus of TXA2R isoforms lead to distinct 
combinations of kinase phosphorylation, and subsequent separated biological processes 
(desensitization or internalization)[92, 93]. Although in many cases the AS-driven replacement or 
addition of potential PTMs remain unknown (i.e. those three N-terminal AS-variants of CXCR4 in 
Fig.3), the reported examples presented above show that the synergistic collaborations of AS and 
PTMs leads to enhanced, context-dependent signaling complexity. That is, IDR-localized AS 
creates alternative PTM patterns leading to different downstream outcomes. Overall, we conclude 
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that diverse signaling carried out by GPCRs use the IDP-AS-PTM toolkit in multiple essential 
ways. 
TFs and the IDP-AS-PTM toolkit 
Co-occurrence of IDRs, AS and PTMs in human TFs in general 
Large portions of eukaryotic TFs have been predicted to contain IDRs, typically covering two-
thirds or more of the TF sequences, and these predictions are in good agreement with 
experimental data[39, 40, 94]. Furthermore, recent work suggests that, for TF families associated 
with development, there is a strong positive correlation between the amount of predicted disorder 
and the complexity of the organism[95]. 
In human TFs, their intrinsic disorder is not restricted to DBDs but includes assigned Pfam 
domains outside of the DBD and also not restricted to transactivation domains or protein-
interaction domains. Significantly, predicted IDRs include massive regions that have not yet been 
assigned to a particular type of domain (green boxplot in Fig.4A, top axis). 
In accordance with the distribution of disorder prediction, higher numbers of TFs have AS 
events within the unassigned regions (URs) as compared to those in DBD and NonDBD (Fig.4A, 
purple-border histogram, bottom axis). Likewise, significantly more PTM sites are located within 
the more disordered URs than those in DBD and NonDBD (Fig.4B). Furthermore, the presence of 
multiple types of PTMs in TFs is very common; among the 1345 TF members with PTM 
annotations, 62% of them have more than one type of PTMs (Fig.4C). Besides, 93 of those 1345 
TFs (~7%) are documented to have two or more types of PTMs targeting the same residues 
(totally 202 sites), with lysine being the most frequent site for alternative PTMs (Fig.4D). In 
addition, 882 (~41%) of all the AS regions (totally 2128 regions) contain known PTMs (Fig.5A), 
and for the fully predicted to be ordered AS regions, those with PTMs are about two times less 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
12 
 
than those without PTMs (Fig.5B). That is, most of AS regions with PTMs (94%) are predicted to 
be disordered (red histogram in Fig. 5B); in comparison, only ~70% of AS regions without known 
PTMs show predicted disorder (blue histogram in Fig.5B). Thus, like GPCRs, human TFs 
generally display co-occurrence of IDRs, AS, and PTMs that likely act synergistically to help 
modulate the complicated aspects of transcriptional regulation. 
Transcriptional regulation of NFATs by IDR-localized AS and PTMs 
Extensive evidence indicates that AS and PTMs of TFs commonly alter DNA-binding 
affinity/specificity or their interactions with cofactors in cell- or tissue-specific manner[28, 96-99]. 
Here we present data for one important subfamily––the nuclear factors of activated T-cells 
(NFATs), to show how specific combinations of IDR-localized AS and PTMs affect the detailed 
functions of NFATs. As key regulators in T-cell development and function, NFATs have five 
members sharing a similar DNA-binding domain. Among them, four members (NFATc1-4) are 
specifically regulated by calcineurin (CaN), a Ca2+/calmodulin-dependent serine phosphatase that 
is involved in many important signaling pathways[100]. The distant member, NFAT5, is not 
calcium-related due to the lack of regulatory domain that contains CaN-binding motifs, and it is 
activated by osmotic stress instead. NFATs are of our particular interest because they have been 
confirmed by CD and NMR to contain extremely long disordered domains besides the well-
defined DNA-binding domain[62]. These experimental data agree very well with the disorder 
prediction in Fig.6A. 
These IDRs of NFATs are the main locations where multiple splicing sites occur (Fig.6B). 
NFATs have been suggested to undergo tissue-specific AS events that contribute to isoform-
specific transcriptional abilities[101]. The ten splice isoforms of NFATc1 are presented in Fig.6B. 
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These variants differ in the length of their disordered N- and/or C-terminus, and all the other 
NFAT genes are able to generate multiple AS isoforms in similar manner[101].  
The NFATc proteins undergo multiple PTMs, including phosphorylation of the serine-rich 
regions (SRR1&2) and Serine–Proline repeat motifs (SP1-3), and sumoylation, most of which 
localize within the disordered region (Fig.6C). The large numbers of phosphorylation sites are 
required for maintaining the NFATc molecules within the cytoplasm, whereas dephosphorylation 
of these sites by CaN promotes nuclear import and initiation of target gene expression. These 
regulatory serine sites are phosphorylated by different kinases, specifically by PKA, DYRK, CK1, 
or GSK3 in a hierarchical pattern, creating a complex regulation that may allow for distinctive 
activation profiles in different cell types[102]. The sumoylation of NFATs, which is cell-specific 
and AS-isoform-specific, was recently shown to repress the transcriptional activity and regulate its 
nuclear retention, providing a new regulatory mechanism for NFAT functions[103]. 
To give more structural details, the nuclear localization signals (NLS) contain clusters of 
positively charged residues interspersed with serines (Fig.6C). Four of the five positively charged 
residues are arginines. Having arginines rather than lysines is likely important here because 
arginines form much stronger interactions with phosphates than do lysines. That is, each arginine 
has two hydrogens that are well-placed to form two hydrogen bonds with two phosphate oxygens, 
and it has even been observed that two arginines can bind to a single phosphate with the 
concomitant formation of four hydrogen bonds[104]. Such hydrogen bonding between the 
phosphates and arginines would inactivate the NLS, while dephosphorylation by calcineurin 
would lead to activation and nuclear import. Interestingly, up to 13 different phosphates, most of 
which are rather distant in the sequence from the NLS, are involved in this inactivation, and the 
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collaboration among the phosphates leads to a sensitive, on-off switch-like behavior for the 
nuclear import of NFAT1c[105, 106]. 
AS alter PTM sites of NFATs 
AS-induced PTM changes are observed (Fig.6C and Fig.6D), and related functional 
consequences have been reported in some cases. The final ~150 residues of C-terminal IDR 
contain a second transactivation domain which contain two strong sumoylation sites (K702, 
K914). Sumoylation leads NFATc1 to its subnuclear relocalization and enable NFATc1 to 
suppress expression of its selective target genes (e.g.IL-2)[107]. The isoforms without these two 
sumoylation sites (e.g. isoform A, isoform IA), but contains a weaker sumoylation site K349, does 
not have the selectivity, suggesting the collaboration of AS and PTM bring out fine-tuning of 
NFATc1 functions. The N-terminal-altered AS isoforms of NFATc1 lose the annotated R23 
methylation, but the functions of methylated R23 remains unknown, so does the consequences of 
losing this PTM. Also, the functions of the phosphorylation sites within the disordered C-terminus 
remains unknown. It has been reported that the C-terminal-altered isoform of NFATc1, B-β, fails 
to interact with TNF-α (a target gene of NFATc1) to which the common NFATc1 isoform strongly 
binds[108]. In addition, two alternative N-terminal transactivation domain regions are generated 
by AS in NFATc2, resulting isoforms having differential roles in the control of cell proliferation and 
transformation[109]. It would be very interesting to test whether this different regulation by NFATc 
is related to the AS-altered PTM mentioned above. 
Taken together, the prevalence of the AS sites, as well as the large numbers of PTM sites 
within the IDRs, suggest that the different NFAT molecules utilize the IDP-AS-PTM toolkit for 
functional diversification. 
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Src family kinases (SFKs) and the IDP-AS-PTM toolkit 
SFKs act as important intermediaries regulating a variety of cellular activities, and increased 
activity or overexpression of SFKs can lead to constant activation, which is considered as its 
common mechanism of causing cancers and other diseases[110]. Src is the first identified proto-
oncogene[111], and its gene product is the first protein discovered to have tyrosine kinase 
activity[112]. SFKs generally include nine members that are divided into two groups based on 
sequence identity: Src, Fyn, Yes, Fgr, and Yrk, forming Group A, Lck, Hck, Blk and Lyn in Group 
B. 
Regulatory role of disordered N-terminus of SFKs 
The N-terminal domains of SFKs, including SH4 and Unique, have been confirmed to be 
disordered by NMR[113, 114], which is in good agreement with our prediction (Fig.7A). The other 
important functional regions are the classic regulatory domains SH3 and SH2, the catalytic 
domain SH1, SH2–SH1 linker and a regulatory C-terminal tail (Fig.7B), which are all involved in 
kinase autoinhibitory functions[115]. Remarkably, recent studies have highlighted a more 
complex regulatory mechanism mediated by the disordered SH4 and Unique domains[116-118]. 
Specifically, Unique is not only able to bind to SH3 and lipids, but also interacts with other 
proteins, such as calmodulin, to regulate kinase activities[116]. The lipid binding of Unique may 
change the ligands or substrates accessible to the kinase, thereby possibly inducing distinct 
pathways. This new finding is further supported by a study demonstrating that disordered SH4 
and Unique are directly involved in kinase regulation by using SH3 as a scaffold[117], and these 
three domains form a fuzzy complex[118]. These recent investigations on SH4 and Unique have 
significantly filled the gap between unrecognized functions of the N-terminus and the well-known 
regulatory roles involving in SH2 and SH3. 
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Multiple types of PTMs within the disordered N-terminus of SFKs dynamically control kinase 
anchoring to the membrane. Specifically, all SFKs share the SH4 myristoylation sites (G2), a 
PTM that is necessary but not sufficient for membrane anchoring. Multiple positively charged 
residues at SH4, and the unique lipid binding regions of Unique domain, also markedly contribute 
to lipid binding as well. More importantly, in the case of Src, the lipid interactions with SH4 and 
Unique are disrupted to different extents by different combinations of phosphorylation. Those can 
either be phosphorylation of SH4 S17 by PKA and/or phosphorylation of Unique T37 and/or S75 
by cyclin-dependent kinase (CDK). The lipid binding is disturbed because the phosphorylated 
residues are negatively charged, which electrostatically repels the negatively charged internal 
lipids. In addition, except for Src and Blk, other SFK members all have a conserved SH4 cysteine 
that can be palmitoylated after the N-myristoylation[119]. This dual acylation is critical for kinase 
localization and trafficking, and also promotes the productive plasma membrane binding. 
IDR-localized AS modify PTMs and binding interactions of SFKs 
AS within the disordered N-terminus of SFKs can delete PTM and has strong effects on 
SFKs cellular locations, protein partner binding and signaling pathways. In the case of Lck, the N-
terminus-associated-isoforms not only show tissue-specific distribution, but also are devoid of the 
binding sites for plasma membrane and for other proteins[120] (Fig.7C and Fig.7D). Specifically, 
alternative installation of exon 1 (which encodes the first 10 residues including G2 myristoylation 
site and C3/C5 palmitoylation sites) and 1-prime (which encode 35 residues including a CD4/8 
binding motif) altered these PTMs and bind sites (Fig.7D), thus may impact subcellular location 
and binding interactions of Lck, respectively[120]. Type I Lck variants (without exon 1) are 
speculated to show modified subcellular location and biological functions, the specific alteration 
remains undefined though[114]. The other member, Hck, is reported to generate an AS-variant 
without the plamitoylation site at the SH4 domain, which is required for significant plasma 
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membrane association[121]. As a consequence, the variant of Hck is mainly bound to lysosome 
membrane rather than plasma membrane, and triggers distinct biological responses as compared 
to those of the more common AS isoform of Hck[122]. Similarly, altered N-terminus variants are 
observed in Lyn, generating LynB with 21 missing residues required for protein-binding 
missing[123]. The modified protein–protein interactions between the most common AS isoform of 
Lyn and LynB affect their ability to associate with their antigen receptors in mast cell signaling 
and response[124]. Taking the above studies together, AS and multiple PTMs within the IDRs of 
SFKs provide the IDP-AS-PTM toolkit for multilevel regulation of kinase membrane anchoring, 
protein–protein interactions. 
Discussion 
Following our initial characterization of the functions carried out by IDPs and IDRs[1], we 
discovered that phosphorylation[20] and AS[26] individually show strong preferential mapping to 
IDRs as compared to structured protein regions. Later we noticed that p53 has functionally 
important IDRs that undergo both multiple PTMs as well as nearby AS. This co-localization of 
PTMs and AS means that the two types of modification can in principle work together to produce 
enormous signaling complexity[29]. Note that isoforms from a single gene of p53 arise not only by 
means of AS but also by alternative start or stop sites or by alternative promoter usage[125], but 
these various mechanisms all lead to the same result––the creation of different-length protein 
isoforms from a single gene. Others independently discovered that the same combination of 
features, e.g., co-localized IDRs, AS, and PTMs, are important for regulating the activities of the 
protein B-cell lymphoma 2 (Bcl-2), a protein important for its complicated roles in controlling 
apoptosis[126]. Further support for these concepts is provided by the observed correlations 
between IDPs and the evolution of cell-type diversification, including the modulation of IDP 
function by AS and PTMs[127]. 
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As we began to look for other proteins that cooperatively use IDPs, AS, and PTMs, we found 
that these three features were very seldom considered together: one laboratory would focus on 
PTMs (especially phosphorylation), another on AS, and very few would consider that AS and 
PTMs, especially clusters of PTMs, preferentially occur in IDRs. For example, in our text-mining 
experiment to determine whether various IDR-containing pathways and proteins might use IDP-
AS-PTM toolkit (Supplement Table S1), this tendency to focus on either PTMs or AS is very 
evident in the data in Table S1, where the number of papers that consider both AS and PTMs 
(the 5th column) is far fewer in every case as compared to the number that consider PTMs or AS 
individually (the 3rd and 4th columns). Thus, it was necessary to choose a few important proteins 
and carefully search the literature to determine whether or not there is evidence that IDRs, AS, 
and PTMs collaborate to increase context-dependent signaling complexity. We also noticed that 
very few of the researchers realized that the AS and PTMs they were studying were colocalized 
in IDP regions.   
As result of these investigations, herein we report clear evidence for co-localization of IDRs, 
AS and PTMs for three important signaling proteins, and furthermore we report clear evidence 
that these three features collaborate to enable highly complex, context-dependent signaling that 
is important for cellular differentiation. Furthermore, we have searched in PubMed for various 
IDR-containing pathways and proteins for their presence of PTMs or AS, and the results (Table 
S1) indicate that the use of IDP-AS-PTM toolkit is likely very widespread. What is needed now is 
further detailed study to determine if IDPs, PTMs and AS are indeed all co-localized in individual 
proteins for the various pathways and in the various proteins, and, if so, how do these three 
features collaborate to bring about the complex context-dependent signaling that underlies these 
various important biological processes. In addition, we collected many IDPs that utilize PTM 
codes (or other different names used by different researchers, Table S2), and point out that 
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because multiple PTMs and AS both map to these IDPs (Table S2), it is likely that AS contributes 
to and enhances the complexity of PTM codes. All of these observations support the importance 
of the proposed IDP-AS-PTM toolkit. 
Note that these three protein families exemplify a wide range of signaling proteins, namely a 
membrane receptor family, a transcription factor family, and a kinase family. We did not know in 
advance if these three mechanistically divergent protein families used IDPs, AS, and PTMs to 
create an array of context-dependent signaling outcomes. The result that all three of these very 
different signaling protein families utilize the IDP-AS-PTM toolkit indicates that this toolkit is very 
widely used. Indeed, when we learned that the Nobel Prize was awarded for work on the 
signaling system underlying circadian rhythms[128], we tested whether two of the key proteins 
shown by the Nobel Laureates to underlie these rhythms, namely clock and period[129], also use 
the IDP-AS-PTM toolkit. We found that these key proteins do contain large amounts of predicted 
disorder (data not shown) which contain both multiple PTMs as well as co-localized AS (Table S1 
and further work in progress). 
Additional proteins related to development[31], proteins related to cancer[2], proteins related 
to induction of pluripotent stem cells[7], and proteins that were studied specifically to understand 
the roles of IDRs or flexible regions in their functions[4, 36-38, 130] all show evidence for their 
likely use of the IDP-AS-PTM toolkit (Table S1). One of these proteins, p53, also shows up 
multiple times in Table S2, suggesting that PTM codes should also be considered for all these 
proteins. These data should encourage molecular biologists focusing on cancer or stem cells to 
test for the use of the IDP-AS-PTM toolkit and also for AS-modulated PTM codes for both of 
these processes. 
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The inhibition of NFAT’s NLS depends on up to 13 well separated phosphorylation events, 
and, furthermore, the collaboration among the multiple phosphorylation events leads to a 
sensitive, switch-like on-off regulation of NFAT’s NLS that may also involve simultaneous 
inhibition of the nuclear export signal (NES) upon dephosphorylation[105]. These data were 
interpreted in terms of a “conformational switch” resulting from protein-structure based models of 
allosterism[105, 106]. However, the multiple phosphorylation events are located in IDRs, not 
structured regions, so a classical “conformational switch” seems very unlikely. A potential 
alternative model is provided by the on-off regulation of Sic1-Cdc4 interaction, which also results 
from multiple well separated phosphorylation events of Sic1. Unlike the NFAT “conformational 
switch model” that depends on structure, the model explaining the on-off behavior of Sic1-Cdc4 
interactions is based on a flexible IDP having multiple phosphate groups that bind to a single site, 
so that, at higher levels of phosphorylation, rebinding by one of the other phosphates is the most 
likely event upon dissociation of a currently bound phosphate. However, at low levels of 
phosphorylation, escape is more likely than rebinding. The resulting kinetic model shows switch-
like on-off behavior as the phosphorylation levels are changed [131, 132]. Such a kinetic model 
might also explain how multiple phosphorylations regulate NFAT’s NLS. 
A key question concerns the origin of the IDP-AS-PTM toolkit, and especially the origin of its 
ability to carry out context-dependent signaling. Tissue- or cell-type-specific AS has been solidly 
connected to the rewiring of protein signaling pathways[32, 33]. Also, AS has been solidly 
connected to alterations of gene regulatory networks[26], but to our knowledge it is yet to be 
shown that tissue- or cell-type-specific AS is directly connected to gene regulation. As for PTMs, 
such events have been shown to be both tissue- or cell-type-specific[34, 35] and to be capable of 
rewiring both protein pathways[16] and genetic networks[36-38], but again experiments directly 
connecting tissue- or cell-type-specific PTMs with rewiring protein pathway or genetic networks 
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are currently lacking. Also, it is unclear how tissue- or cell-type-specific PTMs arise. Do these 
arise from tissue- or cell-type specific expression of the proteins responsible for the PTMs or do 
these arise from tissue- or cell-type specific AS that add or remove the site of modification? 
Probably both mechanisms are involved. Thus, we encourage the development of experiments to 
further test the IDP-AS-PTMhypothesis. 
Since context-dependent signaling depends on the capacity of tissue- or cell-type-specific 
PTMs or AS to rewire or remodel protein pathways or gene regulatory networks, it is tempting to 
suggest that this toolkit originated with multicellularity and became more complex as organism 
complexity increased. Indeed, the frequency of AS events has been shown to increase as the 
organism complexity increases[133] and so far AS in many single cell eukaryotes appears to be 
rather limited. However, there is another alternative, namely that the IDP-AS-PTM toolkit 
originated in single cellular organisms. This conjecture rests on the observations that single cell 
eukaryotic organisms have an abundance of IDRs[134], that they have AS events[135] even if 
such events appear to be rare, at least in the single-cell eukaryotes studied so far, that they use 
PTMs for signaling[135], and that they are sometimes observed to exist in quite different cellular 
states[136-138]. Another alternative is that the single-cell organisms having different cellular 
forms use a simpler toolkit consisting of just IDPs and PTMs; indeed, phosphorylation has already 
been shown to be important for the development of different cell types for yeast[135], but it 
remains to be determined for this example whether these important phosphorylation events occur 
in structured or IDP domains. Thus, we encourage the investigation of whether the IDP-AS-PTM 
toolkit or a slightly simpler IDP-PTM toolkit plays important roles in the formation of, or 
maintenance of, the different cell types observed for some single-cell organisms. If the latter, did 
the IDP-PTM toolkit provide a stepping stone to the IDP-AS-PTM toolkit? We look forward to a 
wider recognition of the connections among IDPs, AS and PTMs and to experimental tests of 
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whether these three features do or do not collaborate to form an important developmental toolkit 
that contributed to the evolution of multicellular organisms. 
Finally, here we propose an integration of the context-dependent signaling arising from IDP-
AS-PTM with more standard views of cellular differentiation. Explanations for cell-type 
specialization and specification focus on gene regulatory networks[139], particularly with regard 
to the use of differential gene expression to regulate cell-type specification[140-143]). Attempts to 
explain the advantages of cell specialization are based mainly on multilevel selection theory, 
soma-germ cell line requirements, and what it means to be an “individual”[144-148]. In our view 
these widely discussed concepts likely account for the broad outlines of cellular differentiation, 
but we speculate that gene regulatory networks alone are simply too coarse-grained for 
successful multicellular life. According to this view, the signaling modulations provided by the 
IDP-AS-PTM toolkit lead to the fine-tuning of the cell-cell signaling interactions provided by 
differential gene expression, a fine-tuning brought about by modulating the signaling interactions 
of these very same differentially expressed genes. This fine-tuning is proposed to enable 
individual cells to more appropriately respond to the various signals received from their 
surroundings, thereby promoting the integration of the different cell types into a more successful 
multicellular organism.  
Materials and Methods 
Dataset construction 
The sequences for human GPCRs, NFATs, and SFKs are collected from UniProt. Initially, a 
full list of GPCR members from all species were obtained from the UniProtKB/Swiss-Prot 
document named 7tmrlist.txt. Only human GPCRs were included by searching the single keyword 
“Human” in the species column. A sequence identity cutoff of 100% was used to remove 
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redundancy by using CD-Hit (with other parameters default), and a total of 822 GPCR sequences 
with sequence identity range from 1.5% to 98.7% (average: 20%, standard deviation:10.9%) were 
retrieved. The names of the five families of NFATs and nine families of SFKs are identified from 
[100] and [115], respectively. One study reported herein is to carry out the alignment of disorder 
predictions across the nine SFKs families using the human sequences for these comparisons. 
However, in the human SFKs, the Yes kinase family member is a pseudogene, so the chicken 
Yes sequence was used in place of the human pseudogene for these comparisons. The 
sequence identity of the five NFAT sequences ranges from 26% to 47%, with an average of 36% 
and standard deviation of 8%. The sequence identity of the nine SFK sequences ranges from 
55% to 79%, with an average of 63% and standard deviation of 6.9%. 
The initial set of human TFs sequences (including 1691 gene members belonging to ~70 
families) are retrieved from AminalTFDB database[149], and a sequence identity cutoff of 100% 
was used to remove redundancy. Among the retrieved 1568 sequences, 1392 of them can be 
assigned to 99 specific DNA-binding domains (DBDs) by Pfam. There are also Pfam domains 
outside the DBDs, which are called Non-DBDs. The segments that have not yet been assigned 
with any Pfam domains are named unassigned regions (URs). 
Disorder prediction 
PONDR FIT was used for all of the disorder predictions reported herein. This is a meta-
predictor that uses a neural network to combine the normalized outputs of six different disorder 
predictors, namely PONDR VLXT, PONDR VSL2, PONDR VL3, IUPred, FoldIndex, and TopIDP. 
Overall, this meta-predictor outperforms all of the individual predictors for nearly every protein 
and by an average of about 11%[134]. This predictor can be accessed at the following URL: 
http://disorder.compbio.iupui.edu/ meta predictor.php#PONDR-FIT. 
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Identification of AS events and PTM sites 
AS events were retrieved from UniProt[150] by using the keywords “Event=Alternative 
splicing” in the CC table of the downloaded flat format files. UniProt provides the information on 
how each spliced isoform differs from the canonical sequence and, more importantly, often 
includes the related literature suggesting the functional relevance or tissue distribution of AS-
isoforms. In addition, “alternative spliced variants + protein name” were used to search for 
additional information on tissue-specific AS. 
PTMs information was extracted from both UniProt and PhosphoSitePlus[57]. Annotations in 
UniProt based on sequence similarity were not included in the current study. Phosphorylation, 
acetylation, methylation and sulfation were obtained from “MOD_RES” in the features table (FT) 
of UniProt flat format file. Glycosylation and palmitoylation were retrieved by using “CARBOHYD” 
and “LIPID” keywords, respectively. Other PTMs sites, especially ubiquitination, were obtained in 
PhosphSitePlus.  
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Figure Legends 
Figure 1 Abundance of alternative splicing (AS) and post-translational modifications (PTMs) 
within IDRs of human GPCRs. (A) Distribution of average percentage of predicted disordered 
residues (score >=0.5 predicted by PONDR-FIT predictor [151], green histogram) and AS regions 
(marked purple line) within each region. (B) Distribution of PTMs (stacked bar, multiple colors). 
(C) AS and PTMs may cooperate to further enhance GPCR signaling complexity. Asterisks (*) 
indicate GPCRs with reported tissue/region-specific AS. 
Figure 2. AS-modulated PTMs are mostly localized within IDRs of GPCRs. (A) Fraction of all 
GPCR AS regions with and without known PTMs. (B) Distribution of disorder prediction for AS 
regions with and without known PTMs (red and blue histogram, respectively). X-axis is the range 
of predicted disorder. Y-axis is the percentage of AS regions within each bin. 
Figure 3. IDR-localized AS and PTMs regulate differential CXCR4 signaling. Predicted disorder 
by PONDR-FIT is shown as heat map (lower left), where red and blue indicate predicted disorder 
and order, respectively. A crystal structure of the structured regions (28–303 residues, PDB id: 
3OE9) is represented in blue ribbon. AS generate three tissue-specific isoforms by replacing the 
first five residues at the disordered N-terminus and strongly affect receptor functions. Multiple 
PTM combinations lead to different signaling: sulfation of Y7, Y12, and Y21 regulates receptor-
ligand binding and dimerization[152], and glycosylation of N11 plays a role in masking the 
coreceptor functional activity[153]; Phosphorylation of Y157 is required for activation of the Gi-
independent JAK2/STAT3 pathway[154]. C-terminal PTM combinations have been reported to 
associate with three different biological processes. Specifically, GRK6 phosphorylation (S339), 
and possibly GRK2 phosphorylation (two residues from S346-S348 and S351-S352), lead to 
receptor-arrestin3 binding, G-protein uncoupling and subsequent receptor desensitization. In 
contrast, GRK3 (at the same regions as GRK2, but probably different residues), and GRK6 (S330 
and S339) phosphorylation result in arrestin2 recruitment and subsequent ERK1/2 
activation[155]. Additionally, PKC and GRK6 phosphorylation (S324 or S325, S330 respectively) 
initiate degradation modulated by ubiquitination of K327, K331, and K333[155, 156]. 
Figure 4 Both AS and PTMs of human transcription factors (TFs) are significantly abundant 
within IDRs, and multiple PTMs are very common. (A) Distribution of percentage of predicted 
disorder (Green boxplot) and the number of TFs with annotated AS regions (purple-border 
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histogram) for three different sets of regions, including Pfam DNA-binding domains (DBD), Pfam 
Non-DBD domains (NonDBD) and unassigned regions (URs). Note that each set of region 
contains more outliers than it indicates in the graph, and the default value 1.5 was used to define 
the outliers. The median value for each set is indicated as a thick line. Statistical significance 
between sets was assessed by Wilcoxon rank sum test, and p values are indicated. (B) 
Distribution of PTM sites. Different types of PTMs are indicated in distinct colors. (C) Percentage 
of TFs with 1, 2, 3, 4, >=5 types of PTMs. (D) Multiple PTMs targeting the same residue. 
Figure 5. AS-modulated PTMs are mostly localized within IDRs of TFs. (A) Fraction of all TF AS 
regions with and without known PTMs. (B) Distribution of disorder prediction for AS regions with 
and without known PTMs (red and blue histogram, respectively). X-axis is the range of predicted 
disorder. Y-axis is the percentage of AS regions within each bin. 
Figure 6 NFATs and the IDP-AS-PTM toolkit. (A) Disorder prediction of the five members of 
NFATs (same heat map as Fig.2). (B) The splice variants of NFATc1. The missing regions are 
indicated in dash line and replaced segments are presented in green boxes. (C) Multiple PTMs 
from PhosphoSitePlus and available publications mainly localize within the IDRs of NFATc1. 
PTMs are indicated by different colors. The important IDR-localized functional regions are: two 
calcineurin-binding motifs (PxIxIT and LxVP, x indicates any residues), nuclear localization signal 
(NLS), three serine-proline-rich repeat motifs (SP1–3) and two serine-rich regions (SRR1&2). The 
structure of the second LxVP short motif is from the NFATc1–calcineurin binding complex (384-
390 residues, PDB id: 5SVE)[157]. 
Figure 7 IDR-localized AS regions modulate PTMs and binding interactions of SFKs. (A) Disorder 
prediction of the nine members of SFKs by PONDR-FIT (same heap map as in Fig.2). (B) 
Domain architecture of SFKs: SH4 (yellow), Unique (red), SH3 (blue), SH2 (green), SH1 (tan). 
Linkers are colored in red line. (C) Gene structures and N-terminal alternative variants of Lck 
gene. Exons are shown in colored boxes and introns are shown as lines. (D) Multiple functional 
PTMs of the disordered N-terminal region of Lck. 
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